VOLITIONRX LTD (VNRX) Fundamental Analysis & Valuation

NYSEARCA:VNRX • US9286611077

0.1998 USD
+0 (+0.86%)
At close: Mar 9, 2026
0.1979 USD
0 (-0.95%)
Pre-Market: 3/10/2026, 7:00:03 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VNRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VNRX. VNRX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VNRX have multiple concerns. VNRX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

0

1. VNRX Profitability Analysis

1.1 Basic Checks

  • VNRX had negative earnings in the past year.
  • In the past year VNRX has reported a negative cash flow from operations.
  • VNRX had negative earnings in each of the past 5 years.
  • In the past 5 years VNRX always reported negative operating cash flow.
VNRX Yearly Net Income VS EBIT VS OCF VS FCFVNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of VNRX (-267.93%) is worse than 92.93% of its industry peers.
Industry RankSector Rank
ROA -267.93%
ROE N/A
ROIC N/A
ROA(3y)-192.89%
ROA(5y)-150.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VNRX Yearly ROA, ROE, ROICVNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VNRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VNRX Yearly Profit, Operating, Gross MarginsVNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. VNRX Health Analysis

2.1 Basic Checks

  • VNRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VNRX has more shares outstanding
  • The number of shares outstanding for VNRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, VNRX has a worse debt to assets ratio.
VNRX Yearly Shares OutstandingVNRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VNRX Yearly Total Debt VS Total AssetsVNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • VNRX has an Altman-Z score of -47.96. This is a bad value and indicates that VNRX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VNRX (-47.96) is worse than 94.02% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -47.96
ROIC/WACCN/A
WACC9.79%
VNRX Yearly LT Debt VS Equity VS FCFVNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.35 indicates that VNRX may have some problems paying its short term obligations.
  • With a Current ratio value of 0.35, VNRX is not doing good in the industry: 94.02% of the companies in the same industry are doing better.
  • VNRX has a Quick Ratio of 0.35. This is a bad value and indicates that VNRX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.35, VNRX is doing worse than 94.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.35
VNRX Yearly Current Assets VS Current LiabilitesVNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VNRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.11% over the past year.
  • VNRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.10%.
  • VNRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 128.05% yearly.
EPS 1Y (TTM)36.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)59.1%
Revenue growth 3Y139.31%
Revenue growth 5Y128.05%
Sales Q2Q%32.19%

3.2 Future

  • Based on estimates for the next years, VNRX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.21% on average per year.
  • The Revenue is expected to grow by 149.33% on average over the next years. This is a very strong growth
EPS Next Y30.9%
EPS Next 2Y29.01%
EPS Next 3Y35.8%
EPS Next 5Y32.21%
Revenue Next Year13.26%
Revenue Next 2Y133.83%
Revenue Next 3Y226.45%
Revenue Next 5Y149.33%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
VNRX Yearly Revenue VS EstimatesVNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
VNRX Yearly EPS VS EstimatesVNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. VNRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VNRX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNRX Price Earnings VS Forward Price EarningsVNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNRX Per share dataVNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VNRX's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.01%
EPS Next 3Y35.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VNRX Dividend Analysis

5.1 Amount

  • VNRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VNRX Fundamentals: All Metrics, Ratios and Statistics

VOLITIONRX LTD

NYSEARCA:VNRX (3/9/2026, 8:04:00 PM)

Premarket: 0.1979 0 (-0.95%)

0.1998

+0 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-31
Inst Owners14.98%
Inst Owner Change-38.36%
Ins Owners6.41%
Ins Owner Change23.15%
Market Cap27.48M
Revenue(TTM)1.23M
Net Income(TTM)-23.32M
Analysts80
Price Target2.24 (1021.12%)
Short Float %2.27%
Short Ratio0.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.18%
Min EPS beat(2)-30.72%
Max EPS beat(2)-17.65%
EPS beat(4)1
Avg EPS beat(4)-12.18%
Min EPS beat(4)-30.72%
Max EPS beat(4)1.96%
EPS beat(8)4
Avg EPS beat(8)-0.56%
EPS beat(12)7
Avg EPS beat(12)1.45%
EPS beat(16)8
Avg EPS beat(16)-55.27%
Revenue beat(2)1
Avg Revenue beat(2)-33.04%
Min Revenue beat(2)-71.37%
Max Revenue beat(2)5.28%
Revenue beat(4)1
Avg Revenue beat(4)-42.14%
Min Revenue beat(4)-73.81%
Max Revenue beat(4)5.28%
Revenue beat(8)1
Avg Revenue beat(8)-43%
Revenue beat(12)1
Avg Revenue beat(12)-45.6%
Revenue beat(16)1
Avg Revenue beat(16)-50.84%
PT rev (1m)1.54%
PT rev (3m)-12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.34%
EPS NY rev (3m)3.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)7.85%
Revenue NY rev (3m)8.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.83
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.01
BVpS-0.23
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -267.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-192.89%
ROA(5y)-150.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.07%
Cap/Sales 31.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.35
Altman-Z -47.96
F-Score4
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)104.21%
Cap/Depr(5y)136.83%
Cap/Sales(3y)230.92%
Cap/Sales(5y)4234.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y30.9%
EPS Next 2Y29.01%
EPS Next 3Y35.8%
EPS Next 5Y32.21%
Revenue 1Y (TTM)59.1%
Revenue growth 3Y139.31%
Revenue growth 5Y128.05%
Sales Q2Q%32.19%
Revenue Next Year13.26%
Revenue Next 2Y133.83%
Revenue Next 3Y226.45%
Revenue Next 5Y149.33%
EBIT growth 1Y28.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.89%
OCF growth 3YN/A
OCF growth 5YN/A

VOLITIONRX LTD / VNRX FAQ

What is the ChartMill fundamental rating of VOLITIONRX LTD (VNRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VNRX.


What is the valuation status of VOLITIONRX LTD (VNRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to VOLITIONRX LTD (VNRX). This can be considered as Overvalued.


Can you provide the profitability details for VOLITIONRX LTD?

VOLITIONRX LTD (VNRX) has a profitability rating of 0 / 10.